The current first‐line treatment for patients with HR+/HER2− advanced breast cancer (ABC) involves the use of cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors in combination with ET [3, 4, 5, 6]. This evidence concerns the gene CDK4 and breast carcinoma.